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Martha Askins, Ph.D., an assistant psycho logist in the Department of Pediatrics and the psychosocial director of the Adol.escent
and Young Adult (AYA) Program, helps
an� with their studies in the AYA classroom.
The program helps patients stay on grade l.evel &y offering a hospital school and by coordinating homeboun d education.

Program Addresses
Medical, Psychosodal
1eeds of Young
People with Cancer
by Rebecca Gershenson Smith

A

s recently as 10 years ago, a 15-year-old

facing treatment for cancer likely wou/,d
find herself thrust into a state of limbo

both medically and socially. She probably

would reside on a unit with patients much o/,der or
younger than herself, miss out on several years of
school and related social experiences, and receive
treatments designed for either children or adults.

(Continued on next page)

their normal emotional, social, and
educational development while
receiving treatment for cancer.
According to Dr. Askins, when a
teen receives a diagnosis of cancer,
the family's first reaction is often to
"drop everything and focus on the
cancer." In contrast, AYA Program
coordinators emphasize to teens
and their families the importance
of continuing education and main
taining social relationships.
"Emotionally, it's very helpful
for children to be able to continue
doing many of the same things they
did before they were diagnosed with
cancer, so they learn that while they
do have to focus a lot of energy on
their cancer treatment, the other
areas of their lives can still be
important," Dr. Askins said.
With the help of counselors and
achers in the AYA Program, teenag
ers with cancer can continue their
education by attending their commu
nity schools, receiving homebound
education, or enrolling in the hospital
school, which works in association
with the Houston Independent
School District and has been success
ful at keeping students on grade level.
As difficult as maintaining basic
educational progress in the face of
cancer u·eatment can be, the AYA
Program coordinators aim beyond
minimal educational goals.
'We don't want cancer treatment
to derail those who have aspirations
to go on to college and even farther,"
Dr. Askins said.
Educational counselors help
students prepare for college entrance
exams and guide them through the
college and scholarship application
processes. Of the 40 current patients
or long-term survivors treated at
M. D. Anderson who graduated in the
ass of 2000, about 75% are going on
college, and at least five were in the
top 10% of their class, Dr. Askins said.
At the other end of the con
tinuum, the program also focuses
on helping patients with cognitive
disabilities find a rewarding

"We don't want

cancer treatment to

derail those who have
aspirations to go

on to college and

even farther:'

- Martha Askins, Ph.D.,

Psychosocial Director, AYA Program

educational setting.
To foster the peer interaction
that teenagers often miss out on
while being treated for cancer, M. D.
Anderson has begun housing all
teens in the same area of the hospi
tal. ''We have a unit where all the
inpatient teens come together from
different services, and it's working
very well," Dr. Jeha said.
The program also provides an
area for teens to regularly come
together and socialize, and outings
such as ski trips, symphony concerts,
or visits to the rodeo-give teens the
opportunity to socialize and provide
a respite from the hospital.
These activities, Dr. Askins said,
provide "important opportunities for
the teens to just spend time together
and to share support with peers as
they are going through the u·eaunent
process."
Other services of the AYA Program
include vocational and career guid
ance; support groups and psycho
therapy; computer training; physical
fitness and rehabilitation classes;
counseling on sexuality, fertility,
sperm banking, and body image; an
annual summer camp; and life skills
courses to help teens learn practical
things like how to handle relation
ships and manage personal finances.
All of the AYA Program's psychoso
cial activities are funded by M. D.
Anderson's Children's Art Project,
which also supports educational
programs such as the hospital class
room and scholarships for graduate

and undergraduate students.
Some individual programs are
particularly innovative, such as
providing teens with pagers that allow
them to wait for appointments in a
relaxed setting with other patients
their age, freeing them from what
can be an awkward time in the waiting
room prior to clinic appointments.
Another unique aspect of the AYA
Program is the planned addition of
Kim's Place, which will provide a
recreational area as well as vocational
and psychosocial support to adoles
cents and young adults whose lives
have been affected. by cancer. Con
struction of the facility is made
possible by a donation from the
Women's National Basketball Associa
tion Houston Comets in honor of
Kim Perrot, a Comets player who
died of lung and brain cancer in
1999. Kim's Place will be located in
the Albert B. and Margaret M. Alkek
Hospital at M. D. Anderson and is
expected to open i n 2002.
The AYA Program's focus on the
nontreatment-related aspects of
adolescent patients' lives does more
than make the patients' treatment at
M. D. Anderson more pleasant,
according to Dr. Askins.
"It conveys our feeling of hope,
that they are going to beat their
illness and that they are going to
have a bright future," she said.•
contact Dr. Askins
at (713) 794-4-466 or Dr:Jeha at
(713) 792-0829.
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so the logic was that if the
behind oxygenated cells that
prostaglandins are there in
are more sensitive to radiation.
Similarly, traditional chemo
airge quantity, then they may be
9'1other reason why tumors are
therapy can be used to kill well
radioresistant," said Dr. Milas.
oxygenated cells, allowing the
He and his collaboralors
center of a tumor to become
believed that by inhibiting
oxygenated and thus more
COX-2, prostaglandin synthesis
susceptible to radiation.
would be selectively inhibited in
tumor cells, and tumors would
Molecular radiosensitizers
become more sensitive to
in clinical studies
radiation. Dr. Milas and col
According to Or. Cox, the
leagues have shown that the
main advantage of bioreductive
COX-2 inhibitor SC-236 alone
drugs and the new molecular
can delay growth of tumor cells
agents (such as SC-236 and
in vitro and of murine tumors
C225) is their lack of toxicity.
James D. Cox, M.D., professor and head of the
as well as human tumor xeno
In
addition, most traditional
Division ofRaduttion Oncowgy, is involved in
grafts, and it has a synergistic
radiosensitizers can be used
moving molecular radiosensitizing agentsfrom the
effect when combined with
only in the treatment of solid
laboratory to the clinic, where he meets here with
radiation. COX-2 inhibitors
tumors, whereas the new
patient�.
may indeed work by inhibiting
molecular agents can be used
prostaglandin synthesis, but a�
for all cancers, including
with C225, there may be addileukemias and lymphomas.
and as effective as new molecular
tional mechanisms, including making agents such as C225 and COX-2
Other molecular radiosensitizers,
cells more sensitive to radiation,
including farnesyl transferase inhibi
inhibitors, the new radiosensitizers
shifting cells to more radiosensitive
may eventually prove more useful than tors (targeting the ras pathway of
cell-cycle phases, or inhibiting
cell growth), the blocking antibody
nudeoside analogues in the clinic.
angiogenesis.
Herceptin (targeting HER-2/neu, a
The second class of traditional
cell-growth receptor overexpressed in
radiosensitizers works by targeting
f!lechanisms of classic radiosensitizers
several cancers), and antiangiogenic
hypoxic tumor cells, those that do
Classic radiosensitizers fall under
agents, are being investigated or will
not receive enough oxygen. Most
two main categories: those that are
be investigated in the near future,
tumors grow outward, away from the
used based on the a-;sumption that
said Dr. Milas. According lo Dr. Cox,
blood vessels that supply them with
tumors proliferate faster than normal
however, the emphasis now is on
the oxygen they need to survive.
cells and those that t.arget hypoxic
agents such as C225 and COX-2
Ox'}'gen can diffuse about 100 to 150
tumor cells.
inhibitors that have already exhibited
µm, often leaving an area of hypoxic
Radiosensitizers such as haloge
improvements over traditional radio
cells in t.he center of a tumor. When
nated pyrimidines are used to exploit oxygen is absent, radiation-damaged
sensitizers and are ready or near
the accelerated proliferation of some cells can repair themselves, but when ready for clinical investigation.
tumor cells, but they have not been
Although COX-2 inhibitors are still
oxygen is present, damage inflicted
entirely successful. Like halogenated
by radiation-induced free radicals is
in the preclinical stage of develop
pyrimidines, nucleoside analogues
ment, patients have been enrolled
"fixed" and becomes permanent.
are incorporated imo DNA, where
Thus, oxygen is essentially one of
in pilot studies of C225 as a radio
they inhibiuepair enzymes. However, the best radiosensitizers available.
sensitizer in the treatment of squa
mous ce11 carcinoma of the head
they also alter cell-cycle sensitivity,
"If you irradiate the cell under
creating an advantage over the classic well-oxygenated conditions and
and neck.
pyrimidines. For example, the
"I think we are all enthusiastic
compare that to irradiation under
nucleoside analogues fludarabine
complete hypoxia, then hypoxic cells about the molecular radiosensitizers
and gemcit.abine kill S-phase cells
C225 and COX-2 inhibitors," said Dr.
are about 2.5 to 3 times more radio
by apoptosis, inducing accumulation
resistant," said Or. Milas. However,
Cox. "We not only have the ability to
show interactions of these agents
of G2/M-phase cells, which are the
many classic hypoxic cell sensitizers,
most sensitive to radiation.
with ionizing radiation in the fab and
such as nitroimidazoles, which act
According to James D. Cox, M.D.,
as oxygen substitutes to sensitize
to explore their basic mechanisms,
fessor and head of the Division
but we then have the ability to take
hypoxic cells to radiation damage,
Radiation Oncology at M. D.
these drugs into the patient-care
are highly neurotoxic. Newer
derson, the disadvantage of
environment," he said.•
bioreductive drugs such as mitomy
nucleoside analogues is their syscin C and t:irapazamine, which are
temic toxjcity. Even though the
FoR MORE INFORMATION, contact Dr. Milas
selectively cytotoxic to hypoxic cells,
analogues may be more effective
at (77 3) 792-3263 or Dr. Cox at
have been more successful, as they
than classic agents in their category
(713) 792-3471.
eliminate the hypoxic cells and leave
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